Newton Biocapital's mission is to generate substantial financial and societal value by providing innovative, breakthrough, and affordable solutions to patients.
DIM3 (Disease in management at the 3rd dimension) is a digital healthcare company co-founded in 2012, whose mission is to develop an application to monitor and improve enteral and parenteral nutrition. The company addresses a huge medical need in a space where awareness is currently low.http://www.dim3.com
SYNERGIA is developing a next-generation, small-form, MRI-safe, implanted neurostimulation device for drug-resistant epilepsy, with a range of further therapeutic applications.http://www.synergia-medical.com
Acticor Biotech is a clinical stage biotechnology company, spin-off of INSERM, dedicated to developing an innovative treatment in the therapy of acute thrombotic diseases, including ischemic stroke and pulmonary embolism. Acticor Biotech is built upon the expertise and the results of researches conducted by, the founders: Dr. Martine Jandrot-Perrus at INSERM Paris and Pr. Philippe Billiald at Paris-Sud University.https://acticor-biotech.com/
Sequana Medical is a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders.https://www.sequanamedical.com
EditForce developed a unique DNA/RNA editing technology, based on pentatricopeptide repeat (PPR) protein platform technology. The technology has a distinct feature that enables the editing of not only DNA but also RNA, highlighting its difference compared to other technologies, and is thus expected to be applied to a wide range of fields. The platform technology has also different mechanisms to work and isolated IP from other existing DNA editing technologies.https://www.editforce.co.jp/en/
Established in December of 2005, J-Pharma’s mission is to help mankind by creating and developing novel pharmaceuticals based upon a human-genomic approach; an approach where people with specific diseases are treated with novel and selective agents. J-Pharma’s intellectual property (IP) embraces the notion that cell membrane transporters are tightly associated to many diseases. In addition to drug molecules that target specific transporters, J-Pharma has discovered several important drug transporters within the human body that may be used to evaluate and optimize pharmacokinetics of new drug candidates. We believe that J-Pharma’s pipelines will lead to new agents and processes (i.e. diagnostic methods) and will increase the quality of life for an ageing population in industrialized countries. J-Pharma’s overall goal is to contribute globally to the maintenance of human health and improve human welfare through the creation of new drugs.
Aboleris Pharma is developing new immunomodulators for immune mediated diseases. The company has two programs: 1) a monoclonal antibody anti-CD45RC (ABIS-45RC) and 2) the cytokine IL-34 (ABIS-34).http://aboleris-pharma.com
Metabolys is developing a small molecule to treat patients suffering from metabolic diseases, especially Non Alcoholic Steato-Hepatitis (NASH). This small molecule (MTBL0036) targets the mitochondrial pyruvate carrier (MPC). Pyruvate lies at a central biochemical node connecting carbohydrate, amino acid, and fatty acid metabolism, and the regulation of pyruvate flux into mitochondria represents a critical step in intermediary metabolism impacting numerous diseases. With the first preclinical data generated by the company, the MTBL0036 seems to be the most efficient of all the orally active anti-NASH and antifibrotic candidates in development when assessed with the STAM animal model of NASH. Easy to produce, it seems to be very efficacious for inhibiting both inflammation and liver cell destruction and could potentially be used complementary of other anti-NASH candidates.
DeuterOncology is focused on the pre-clinical validation and development of DO-2, a novel MET and RAS pathway inhibitor sublicensed (worldwide rights outside of greater China) from OCTIMET Oncology NV and originally licensed from Janssen Pharmaceutica in 2017. DeuterOncology’s portfolio contains a sublicense to the all OCTIMET compounds, includes a clinical-stage MET kinase inhibitor that has been evaluated in both a monotherapy and combination therapy setting in cancer patients in Europe. DeuterOncology works together with a broad established network of collaborators across the world to try to bring new solutions to cancer patients
Perseus Proteomics is Therapeutic antibody development targeting transferrin receptor for various blood cancer diseases and antibody drug discovery platform base on phage display
The company licensed out 2 product candidates and possesses 1 internal product candidate (PPMX-T003) for hematologic cancer (Polycythemia Vera) at Ph1 in Japan since 2019.
PPMX-T003, targets a transferrin receptor (TfR) that is expressed on the cell membrane and regulates cellular iron uptake. The cellular iron uptake is essential for cell survival and proliferation. As TfR is highly expressed in many cancer cells, it is widely known that the inhibition of iron uptake depletes its levels within cells, leading to cell death. Many attempts to achieve inhibition of iron uptake have been made in the healthcare industry for a long time, but without success. Through the phage display method, the fully human antibody, PPMX-T003, which kills cancer cells effectively with its extremely potent inhibitory activity against iron uptake.